Results of high-dose chemotherapy/hematopoietic stem cell transplantation (HDC/HSCT) for patients in first relapse of Hodgkin’s lymphoma after chemotherapy for advanced disease.
| HDC . | n . | ~ 5 y† PFS % . | Reference . |
|---|---|---|---|
| Abbreviations: PFS, progression-free survival (†range 4 to 6 years to estimate); CR, complete remission; BEAM, carmustine, etoposide, cytosine arabinoside, melphalan; BCNU/ETOP/Cy, carmustine, etoposide, cyclophosphamide; fTBI, fractionated TBI; ETOP, etoposide; Cy, cyclophosphamide; CBV±P, cyclophosphamide, carmustine, etoposide ± cisplatin; BCNU/ETOP/Cy, carmustine, etoposide, cyclophosphamide; BEAC, carmustine, etoposide, cytosine arabinoside, cyclophosphamide | |||
| BEAM | 52 | 47 | 22 |
| BCNU/ETOP/Cy fTBI/ETOP/Cy | 43 | ~40 | 26 |
| CBV | 85 | 40 | 77 |
| CBV±P | 58 | 61 | 78 |
| BCNU/ETOP/Cy fTBI/ETOP/Cy | 47 | ~50 | 79 |
| CBV | 42 | 44 | 80 |
| BEAM (n = 81) CBV (n = 28) Other (n = 19) fTBI-containing (n = 11) | 139 | 45 | 73 |
| CBV (n = 40) fTBI/ETOP/Cy (n = 20) | 60 | 50 | 7 |
| CBV (50%) BEAM (20%) BEAC (14%) fTBI + variable chemotherapies (10%) | 216 | 37 | 81 |
| HDC . | n . | ~ 5 y† PFS % . | Reference . |
|---|---|---|---|
| Abbreviations: PFS, progression-free survival (†range 4 to 6 years to estimate); CR, complete remission; BEAM, carmustine, etoposide, cytosine arabinoside, melphalan; BCNU/ETOP/Cy, carmustine, etoposide, cyclophosphamide; fTBI, fractionated TBI; ETOP, etoposide; Cy, cyclophosphamide; CBV±P, cyclophosphamide, carmustine, etoposide ± cisplatin; BCNU/ETOP/Cy, carmustine, etoposide, cyclophosphamide; BEAC, carmustine, etoposide, cytosine arabinoside, cyclophosphamide | |||
| BEAM | 52 | 47 | 22 |
| BCNU/ETOP/Cy fTBI/ETOP/Cy | 43 | ~40 | 26 |
| CBV | 85 | 40 | 77 |
| CBV±P | 58 | 61 | 78 |
| BCNU/ETOP/Cy fTBI/ETOP/Cy | 47 | ~50 | 79 |
| CBV | 42 | 44 | 80 |
| BEAM (n = 81) CBV (n = 28) Other (n = 19) fTBI-containing (n = 11) | 139 | 45 | 73 |
| CBV (n = 40) fTBI/ETOP/Cy (n = 20) | 60 | 50 | 7 |
| CBV (50%) BEAM (20%) BEAC (14%) fTBI + variable chemotherapies (10%) | 216 | 37 | 81 |